Beautiful Virgin Islands

Thursday, Oct 30, 2025

Magic mushrooms show promise in treatment for depression, study says

Magic mushrooms show promise in treatment for depression, study says

Trial suggests psilocybin combined with psychological therapy is as effective as antidepressant drug

Magic mushrooms have a long and rich history. Now scientists say they could play an important role in the future, with their active ingredient a promising treatment for depression.

The results from a small, phase two clinical trial have revealed that two doses of psilocybin appears to be as effective as the common antidepressant escitalopram in treating moderate to severe major depressive disorder, at least when combined with psychological therapy.

“I think it is fair to say that the results signal hope that we may be looking at a promising alternative treatment for depression,” said Dr Robin Carhart-Harris, head of the centre for psychedelic research at Imperial College London and a co-author of the study.

Carhart-Harris said psilocybin was thought to work in a fundamentally different way to escitalopram. While both act on the brain’s serotonin system, he said escitalopram seemed to work by helping people tolerate stress more easily.

“With a psychedelic it is more about a release of thought and feeling that, when guided with psychotherapy, produces positive outcomes,” he said, adding participants given psilocybin had often reported feeling they had got more fully to the root of why they were depressed.

However, Carhart-Harris cautioned against seeking out magic mushrooms – a class A drug in the UK – for DIY treatment.

Dr Robin Carhart-Harris, co-author of the study: ‘The results signal hope that we may be looking at a promising alternative treatment for depression.’


“That would be an error of judgment,” he said. “We strongly believe that the … psychotherapy component is as important as the drug action.”

The £1m trial builds on previous work by the team exploring how psilocybin affects the brain, and an earlier clinical trial in which the drug helped alleviate treatment-resistant depression in 12 patients.

Over the six-week trial, 30 out of 59 adults with moderate to severe major depressive disorder were randomly allocated to receive two 25mg doses of psilocybin three weeks apart – a dose that Carhart-Harris said was high enough to produce the kind of experiences often described as existential or even “mystical”. The day after the first dose of psilocybin, this group began a daily placebo.

The other 29 participants were given two very low, or “inactive”, doses of psilocybin three weeks apart. This was to ensure any differences in outcomes between the groups would not simply be down to the expectation of being given psilocybin. The day after the first dose of psilocybin, this group began a daily dose of escitalopram, the strength of which increased over time.

Each psilocybin session – which lasted six hours, including a three- to four-hour “trip” for those on the high dose – was supervised by at least two mental health professionals, with the participants lying on their back, propped up by pillows and listening to emotionally evocative neoclassical music.

All participants received psychological therapy the day after a psilocybin session, as well as a phone or video call in the week after the first dose.

The results, published in the New England Journal of Medicine, reveal that after six weeks both groups showed, on average, a decrease in the severity of depressive symptoms, according to scores from a questionnaire completed by the participants. However, this reduction did not differ significantly between the two groups.

“Psilocybin therapy, as we predicted, works more quickly than escitalopram,” said Carhart-Harris.

He added that results from other scales were “tantalisingly suggestive of potential superiority of psilocybin therapy” not only for depression but other aspects of wellbeing. He warned the findings were not conclusive as the team did not take into account the number of comparisons being made.

However, the team noted that 57% of patients in the high-dose psilocybin group were judged to be in remission for their depression by the end of the six weeks, compared with 28% in the escitalopram group, while neither group had serious side-effects.

While the team said the results were promising, others said the study was not big enough to draw firm conclusions. Among other limitations, the majority of participants were white, middle-aged, highly educated and male, while participants may have been able to guess which treatment they received and there was no group given a placebo and therapy alone.

Anthony Cleare, professor of psychopharmacology at King’s College London, said the study provided “some of the most powerful evidence to date that psychedelics may have a role to play in the treatment of depression”.

However, he said far more data was needed before drugs such as psilocybin could be used outside of research, adding they would not replace existing treatments for depression.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
UK and Vietnam Sign Landmark Migration Deal to Fast-Track Returns of Irregular Arrivals
UK Drug-Pricing Overhaul Essential for Life-Sciences Ambition, Says GSK Chief
Princesses Beatrice and Eugenie Temporarily Leave the UK Amid Their Parents’ Royal Fallout
UK Weighs Early End to Oil and Gas Windfall Tax as Reeves Seeks Investment Commitments
UK Retail Inflation Slows as Shop Prices Fall for First Time Since Spring
Next Raises Full-Year Profit Guidance After Strong Third-Quarter Performance
Reform UK’s Lee Anderson Admits to 'Gaming' Benefits System While Advocating Crackdown
United States and South Korea Conclude Major Trade Accord Worth $350 Billion
Hurricane Melissa Strikes Cuba After Devastating Jamaica With Record Winds
Vice President Vance to Headline Turning Point USA Campus Event at Ole Miss
U.S. Targets Maritime Narco-Routes While Border Pressure to Mexico Remains Limited
Bill Gates at 70: “I Have a Real Fear of Artificial Intelligence – and Also Regret”
Elon Musk Unveils Grokipedia: An AI-Driven Alternative to Wikipedia
Saudi Arabia Unveils Vision for First-Ever "Sky Stadium" Suspended Over Desert Floor
Amazon Announces 14 000 Corporate Job Cuts as AI Investment Accelerates
UK Shop Prices Fall for First Time Since March, Food Leads the Decline
London Stock Exchange Group ADR (LNSTY) Earns Zacks Rank #1 Upgrade on Rising Earnings Outlook
Soap legend Tony Adams, long-time star of Crossroads, dies at 84
Rachel Reeves Signals Tax Increases Ahead of November Budget Amid £20-50 Billion Fiscal Gap
NatWest Past Gains of 314% Spotlight Opportunity — But Some Key Risks Remain
UK Launches ‘Golden Age’ of Nuclear with £38 Billion Sizewell C Approval
UK Announces £1.08 Billion Budget for Offshore Wind Auction to Boost 2030 Capacity
UK Seeks Steel Alliance with EU and US to Counter China’s Over-Capacity
UK Struggles to Balance China as Both Strategic Threat and Valued Trading Partner
Argentina’s Markets Surge as Milei’s Party Secures Major Win
British Journalist Sami Hamdi Detained by U.S. Authorities After Visa Revocation Amid Israel-Gaza Commentary
King Charles Unveils UK’s First LGBT+ Armed Forces Memorial at National Memorial Arboretum
At ninety-two and re-elected: Paul Biya secures eighth term in Cameroon amid unrest
Racist Incidents Against UK Nurses Surge by 55%
UK Chancellor Rachel Reeves Cites Shared Concerns With Trump Administration as Foundation for Early US-UK Trade Deal
Essentra plc: A Closer Look at a UK ‘Penny Stock’ Opportunity Amid Market Weakness
U.S. and China Near Deal to Avert Rare-Earth Export Controls Ahead of Trump-Xi Summit
Justin time: Justin Herbert Shields Madison Beer with Impressive Reflex at Lakers Game
Russia’s President Putin Declares Burevestnik Nuclear Cruise Missile Ready for Deployment
Giuffre’s Memoir Alleges Maxwell Claimed Sexual Act with Clooney
House Republicans Move to Strip NYC Mayoral Front-Runner Zohran Mamdani of U.S. Citizenship
Record-High Spoiled Ballots Signal Voter Discontent in Ireland’s 2025 Presidential Election
Philippines’ Taal Volcano Erupts Overnight with 2.4 km Ash Plume
Albania’s Virtual AI 'Minister' Diella Set to 'Birth' Eighty-Three Digital Assistants for MPs
Tesla Unveils Vision for Optimus V3 as ‘Biggest Product of All Time’, Including Surgical Capabilities
Francis Ford Coppola Auctions Luxury Watches After Self-Financed Film Flop
Convicted Sex Offender Mistakenly Freed by UK Prison Service Arrested in London
United States and China Begin Constructive Trade Negotiations Ahead of Trump–Xi Summit
U.S. Treasury Sanctions Colombia’s President Gustavo Petro over Drug-Trafficking Allegations
Miss USA Crowns Nebraska’s Audrey Eckert Amid Leadership Overhaul
‘I Am Not Done’: Kamala Harris Signals Possible 2028 White House Run
NBA Faces Integrity Crisis After Mass Arrests in Gambling Scandal
Swift Heist at the Louvre Sees Eight French Crown Jewels Stolen in Under Seven Minutes
U.S. Halts Trade Talks with Canada After Ontario Ad Using Reagan Voice Triggers Diplomatic Fallout
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
×